Core Viewpoint - The company, Borui Pharmaceutical, has announced a delay in the expected completion dates for several fundraising investment projects, pushing them to March 2027 due to regulatory approval processes and additional construction needs [2][3]. Trading Information Summary - On December 31, 2025, Borui Pharmaceutical's stock closed at 49.06 yuan, down 0.69%, with a turnover rate of 0.89% and a trading volume of 37,800 shares, amounting to a total transaction value of 186 million yuan [1]. - The net outflow of main funds was 11.73 million yuan, accounting for 6.32% of the total transaction value, while retail investors saw a net inflow of 5.07 million yuan, representing 2.73% of the total [2]. Company Announcement Summary - The Board of Directors approved a proposal to delay the expected completion dates for several fundraising investment projects to March 2027, which include the construction of an inhalation and chemical drug production base and a biopharmaceutical research center [2][3]. - The delay is attributed to products being in the approval stage and the need for additional construction of an automated warehouse, which requires synchronized acceptance [2][3]. - The delay does not change the intended use of the raised funds and does not affect the company's normal operations [2][3]. Internal Governance and Management Systems - The company has established an internal audit management system to ensure independent auditing of internal controls, financial information, and operational activities [4]. - A foreign exchange transaction management system has been implemented to mitigate exchange rate risks and ensure fund security, prohibiting speculative activities [5]. - The company has also set up a fundraising management method to regulate the use and supervision of raised funds, ensuring they are used exclusively for designated projects [6]. - A management system for shares held by directors and senior management has been created to regulate share transactions and disclosures [7].

Core Viewpoint - 博瑞医药 has experienced a stock price increase and has announced a delay in several fundraising projects, which will not affect the company's normal operations or the intended use of funds [1][2][3]. Group 1: Stock Performance - As of December 26, 2025, 博瑞医药's stock closed at 50.21 yuan, up 3.31% from the previous week [1]. - The stock reached a high of 50.97 yuan and a low of 48.22 yuan during the week [1]. - The company's total market capitalization is 20.757 billion yuan, ranking 22nd in the chemical pharmaceutical sector and 947th among all A-shares [1]. Group 2: Company Announcements - 国联民生证券 conducted a site inspection for 博瑞医药's 2025 annual continuous supervision, finding no violations in governance, information disclosure, or major investments [2][6]. - 博瑞医药's board approved a resolution to postpone the expected operational status date for several fundraising projects to March 2027 due to pending product approvals and the addition of an automated warehouse [2][3]. - The delay affects projects including the inhalation and chemical drug formulation production base and the biopharmaceutical R&D center [2][3]. Group 3: Internal Governance - 博瑞医药 has established an internal audit system to oversee internal controls, financial information, and operational activities [4]. - The company has implemented a management system for forward foreign exchange transactions to mitigate exchange rate risks [4]. - A fundraising management method has been developed to ensure that raised funds are used specifically for intended projects and are subject to strict oversight [5][6]. Group 4: Management Regulations - 博瑞医药 has set up a management system for shares held by directors and senior management, regulating trading periods and disclosure requirements [7].

Core Viewpoint - The company, Borui Pharmaceutical, reported a stock price of 49.4 yuan as of December 30, 2025, with a slight decline of 0.66% and a trading volume of 41,400 shares, amounting to a total transaction value of 205 million yuan [1]. Trading Information Summary - On December 30, the main funds experienced a net outflow of 20.59 million yuan, accounting for 10.03% of the total transaction value; retail investors saw a net inflow of 12.39 million yuan, representing 6.04% of the total [2]. - The company’s stock trading saw a turnover rate of 0.98% [1]. Company Announcements Summary - The underwriting and sponsoring company, Guolian Minsheng Securities, conducted an on-site inspection of Borui Pharmaceutical for its 2025 annual continuous supervision work, confirming that the company has a sound governance structure and complies with regulations regarding fundraising and investment [2]. - The board of directors approved a proposal to postpone the expected operational status date for several fundraising projects to March 2027, due to pending product approvals and the need for additional construction of an automated warehouse [2][3]. Internal Governance and Audit - Borui Pharmaceutical established an internal audit management system to ensure independent auditing of internal controls, financial information, and operational activities, with regular reporting to the audit committee [4]. - The company also implemented a foreign exchange trading management system to mitigate exchange rate risks and ensure the safety of funds, prohibiting speculative activities [5]. Fundraising Management - The company has set up a fundraising management method to regulate the storage, use, and supervision of raised funds, ensuring they are used exclusively for designated projects and not for financial investments [6]. - Any changes in fundraising projects or surplus fund usage must go through board or shareholder meeting approval, with biannual progress checks and annual verification reports from accounting firms [6]. Shareholding Management - Borui Pharmaceutical has established a management system for shares held by directors and senior management, outlining restrictions on share transfers and trading periods, as well as disclosure requirements [7].

博瑞生物医药（苏州）股份有限公司 内部审计制度 一、总则 第一条 为了规范博瑞生物医药（苏州）股份有限公司（以下简称"公司"） 内部审计工作，充分发挥内部审计的监督管理职能，提高企业管理水平，加强 公司内部控制，根据《中华人民共和国审计法》、《中华人民共和国审计署关 于内部审计工作的规定》、《上海证券交易所股票科创板上市规则》等法律、 法规、规范性文件及《博瑞生物医药（苏州）股份有限公司章程》（以下简称 "公司章程"）的规定，结合公司实际情况，制定本制度。 第二条 本制度所称内部审计，是指公司内部审计机构或人员，对公司内部 控制和风险管理的有效性、财务信息的真实性和完整性以及经营活动的效率和 效果等开展的审查与评价活动。 第三条 本制度适用于公司及下属各部门、分公司、控股子公司以及公司能 够对其实施重大影响的参股公司(以下简称"参股公司")。 二、内部审计机构设置和人员配备 第四条 公司在董事会下设审计委员会，内部审计机构为公司审计委员会专 门工作机构，负责公司内部审计及内部控制相关工作，配备与公司规模以及工 作量相匹配的专职工作人员，在审计委员会领导下独立开展内部审计工作。必 要时经批准可聘请外部人员或审计 ...

Group 1 - The company, Borui Pharmaceutical, announced that its fourth board meeting was held on December 29, 2025, to discuss the proposal regarding the extension of fundraising investment projects [1] - The meeting took place in the C27 conference room [1]

博瑞生物医药（苏州）股份有限公司 第一条 为规范博瑞生物医药（苏州）股份有限公司（以下简称"公司"）远 期外汇交易业务及相关信息披露工作，加强对远期外汇交易业务的管理，防范汇 率风险，保证公司资金安全，根据《中华人民共和国公司法》、《中华人民共和国 证券法》、《上海证券交易所科创板股票上市规则》等法律、法规和规范性文件， 以及《公司章程》等有关规定，结合公司实际情况，制定本制度。 第二条 本制度所称远期外汇交易特指在银行等金融机构办理的规避和防范 汇率风险的远期外汇交易业务，包括远期结售汇业务、人民币外汇掉期业务等低 风险外汇交易。 远期结售汇业务是指与银行等金融机构签订远期结售汇合同，约定将来办理 结汇或售汇的外汇币种、金额、汇率和期限，到期再按照该远期结售汇合同约定 的币种、金额、汇率办理结汇或售汇的业务。 人民币外汇掉期业务是指在委托日同时与银行等金融机构约定两笔金额一 致、买卖方向相反、交割日期不同的人民币对同一外币的买卖交易，并在两笔交 易的交割日按照该掉期合约约定的币种、金额、汇率办理的结汇或售汇业务。 第三条 公司从事远期外汇交易业务应遵守国家有关法律、法规、规范性文 件的规定，还应遵守本制度的 ...

募集资金使用管理办法 第一章 总则 第一条 为规范博瑞生物医药（苏州）股份有限公司（以下简称"公司"） 募集资金管理，提高募集资金使用效率，根据《中华人民共和国公司法》《中华 人民共和国证券法》《上市公司证券发行注册管理办法》《上市公司募集资金监 管规则》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市 公司自律监管指引第1号——规范运作》等相关法律法规、规范性文件以及《博 瑞生物医药（苏州）股份有限公司章程》（以下简称"公司章程"）规定，结合 公司实际情况，特制定本办法。 第二条 本办法所称募集资金是指公司通过发行股票或者其他具有股权性 质的证券，向投资者募集并用于特定用途的资金，但不包括公司实施股权激励计 划募集的资金。本办法所称超募资金是指实际募集资金净额超过计划募集资金金 额的部分。 第三条 募集资金到位后，公司应及时办理验资手续，由符合《证券法》 规定的会计师事务所审验并出具验资报告。并按照公开信息披露所承诺的资金使 用计划，组织募集资金的使用工作。 第四条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产 业政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于 ...

博瑞生物医药（苏州）股份有限公司 董事和高级管理人员所持本公司股份及其变动管理制度 第一条 为规范博瑞生物医药（苏州）股份有限公司（以下简称"公司"）对 董事、高级管理人员所持本公司股份及其变动的管理，维护证券市场秩序，根据 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司董事和高级管理人员所持本公司股份及其 变动管理规则》《上市公司股东减持股份管理暂行办法》《上海证券交易所上市公 司自律监管指引第 15 号——股东及董事、高级管理人员减持股份》《上海证券交 易所科创板股票上市规则》（以下简称"《上市规则》"）等有关法律法规、规范性 文件和《博瑞生物医药（苏州）股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，结合公司具体情况，制定《博瑞生物医药（苏州）股份有限公司董 事和高级管理人员所持本公司股份及其变动管理制度》（以下简称"本制度"）。 第二条 本制度适用于公司董事、高级管理人员所持本公司股份及其变动管 理。 第三条 公司董事和高级管理人员所持本公司股份，是指登记在其名下和利 用他人账户持有的所有本公司股份。上述人员从事融资融券 ...

证券代码：688166 证券简称：博瑞医药 公告编号：2025-107 博瑞生物医药（苏州）股份有限公司 第四届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、董事会会议审议情况 （一）审议通过《关于募集资金投资项目延期的议案》 为优化公司整体产能布局并匹配业务发展的实际需要，公司对厂房规划进行 了审慎评估与优化调整。拟将博瑞吸入剂及其他化学药品制剂生产基地和生物医 药研发中心新建项目（一期）、博瑞生物医药（苏州）股份有限公司吸入剂及其 他化学药品制剂生产基地和生物医药研发中心新建项目（二期）达到预定可使用 状态的时间由 2025 年 12 月延长至 2027 年 3 月，创新药制剂和原料生产基地建 设项目（一期）中苏州制剂生产基地达到预定可使用状态的时间由 2026 年 1 月 延期至 2027 年 3 月。 具体内容详见公司同日披露于上海证券交易所网站的《关于募集资金投资项 目延期的公告》。 表决结果：11 票同意；0 票反对；0 票弃权。 （二）审议通过《关于修订及制定公司部分内部治理 ...

国联民生证券承销保荐有限公司 关于博瑞生物医药（苏州）股份有限公司 募投项目延期的核查意见 国联民生证券承销保荐有限公司（以下简称"民生证券"）作为博瑞生物医药 （苏州）股份有限公司（以下简称"博瑞医药"或"公司"）向不特定对象发行可转 换公司债券、向特定对象发行股票持续督导的保荐机构，履行持续督导职责，并 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》 等规范性法律文件的要求，对博瑞医药募投项目延期事宜进行了审慎核查，核查 情况及意见如下： 一、募集资金基本情况 （一）2022 年公开发行可转换公司债券 根据中国证券监督管理委员会下发的《关于同意博瑞生物医药（苏州）股份 有限公司向不特定对象发行可转换公司债券注册的批复》（证监许可[2021]3551 号），2022 年 1 月 4 日，公司按面值发行 46,500.00 万元可转债，每张面值为人 民币 100 元，共计 465 万张。本次公开发行可转换公司债券募集资金总额扣除包 含民生证券保荐承销费在内的所有不含税的发行费用人民币 816.88 万元后，实 际募集资金净额为人民币 45,683.12 万元。上述募集资金已于 202 ...